ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the 13 Best Low Risk High Growth Stocks to Buy. The company witnesses ...

An independent distributor in their pharmacy with a range of biopharmaceutical products on display. ADMA Biologics, Inc. (NASDAQ:ADMA) said that the transaction was in line with the Rule 10b5-1 ...

ADMA Biologics, Inc.’s ADMA is witnessing a phenomenal run this year. Its shares have surged a whopping 262.1% in the year so far against the industry’s decline of 2.1%. The stock has been ...

On ADMA's fourth-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.

ADMA Biologics shares were 15% higher, at $25.25, ... Its products infuse people with primary immunodeficiency with the virus-blocking antibodies their own bodies can't make.

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to ...

Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides its blood plasma for the manufacture of its products.

ADMA had filed a Biologics License Application (BLA) for its lead product candidate, RI-002, with the U.S. Food and Drug Administration (FDA), which accepted the BLA on September 18, 2015.

ADMA Biologics, which competes with Takeda TAK and Grifols GRFS in the U.S. market for plasma-derived products, should maintain momentum in the upcoming quarters. The targeted market has ...